BofA raised the firm’s price target on BioCryst to $11 from $10 and keeps a Buy rating on the shares after the company hosted an R&D analyst day and provided an overview of its development pipeline and discovery platform. Near-term, the Orladeyo launch continues to be the main driver to the firm’s valuation, contributing $12 to its new $11 target, while the firm reiterates a Buy rating on shares given its continued view that the current stock price undervalues the long-term Orladeyo opportunity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BCRX:
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BioCryst price target lowered to $20 from $25 at TD Cowen
- BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®
- BioCryst announces drug discovery updates ahead of R&D day
- BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months
